A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection.
The hallmark of acute allograft rejection is infiltration of the inflamed graft by circulating leukocytes. We studied the role of fractalkine (FKN) and its receptor, CX(3)CR1, in allograft rejection. FKN expression was negligible in nonrejecting cardiac isografts but was significantly enhanced in rejecting allografts. At early time points, FKN expression was particularly prominent on vascular tissues and endothelium. As rejection progressed, FKN expression was further increased, with prominent anti-FKN staining seen around vessels and on cardiac myocytes. To determine the capacity of FKN on endothelial cells to promote leukocyte adhesion, we performed adhesion assays with PBMC and monolayers of TNF-alpha-activated murine endothelial cells under low-shear conditions. Treatment with either anti-FKN or anti-CX(3)CR1-blocking Ab significantly inhibited PBMC binding, indicating that a large proportion of leukocyte binding to murine endothelium occurs via the FKN and CX(3)CR1 adhesion receptors. To determine the functional significance of FKN in rejection, we treated cardiac allograft recipients with daily injections of anti-CX(3)CR1 Ab. Treatment with the anti-CX(3)CR1 Ab significantly prolonged allograft survival from 7 +/- 1 to 49 +/- 30 days (p < 0.0008). These studies identify a critical role for FKN in the pathogenesis of acute rejection and suggest that FKN may be a useful therapeutic target in rejection.
Robinson
L A
LA
Departments of. Pediatrics, Medicine, and Pathology, Duke University Medical Center, Durham, NC 27710, USA. robin025@mc.duke.edu
Nataraj
C
C
Thomas
D W
DW
Howell
D N
DN
Griffiths
R
R
Bautch
V
V
Patel
D D
DD
Feng
L
L
Coffman
T M
TM
D000818:Animals; D002448:Cell Adhesion / Q000276:immunology; D002478:Cells, Cultured; D054428:Chemokine CX3CL1; D020523:Chemokines, CX3C; D019743:Chemokines, CXC / Q000096:biosynthesis / Q000378:metabolism / Q000502:physiology*; D004730:Endothelium, Vascular / Q000276:immunology / Q000378:metabolism; D006084:Graft Rejection / Q000276:immunology* / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D006085:Graft Survival / Q000276:immunology; D016027:Heart Transplantation / Q000276:immunology* / Q000473:pathology; D007106:Immune Sera / Q000008:administration & dosage; D007274:Injections, Intraperitoneal; D007963:Leukocytes, Mononuclear / Q000502:physiology; D008565:Membrane Proteins / Q000096:biosynthesis / Q000378:metabolism / Q000502:physiology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D008822:Mice, Transgenic; D054367:Receptors, CXCR3; D019707:Receptors, Chemokine / Q000276:immunology / Q000502:physiology*; D014184:Transplantation, Homologous; D014407:Tumor Cells, Cultured
D054428:Chemokine CX3CL1; D020523:Chemokines, CX3C; D019743:Chemokines, CXC; C515539:Cx3cl1 protein, mouse; C515188:Cxcr3 protein, mouse; D007106:Immune Sera; D008565:Membrane Proteins; D054367:Receptors, CXCR3; D019707:Receptors, Chemokine